Drug intelligence / Profile preview

donitabart

Development stage: Phase 1
Lead developer: Biocad
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Donitabart (BCD-245) is an anti-GD2 monoclonal antibody developed by Biocad for the treatment of neuroblastoma and other GD2-expressing tumors, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and soft tissue sarcoma. It targets the disialoganglioside GD2 antigen on tumor cells and exerts its antineoplastic effects primarily through antibody-dependent cell-mediated cytotoxicity (ADCC), leading to the destruction of GD2-positive cancer cells. The drug is administered intravenously and is currently in Phase 1 clinical trials for relapsed/refractory neuroblastoma[1][2][3][4].

Other names: donitabart

Targets

GD2

Beyond the preview

Go deeper on donitabart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donitabart.

Explore the full profile